222 related articles for article (PubMed ID: 25603872)
1. [Advances on driver oncogenes of non-small cell lung cancer].
Zhao J; Xiong J
Zhongguo Fei Ai Za Zhi; 2015 Jan; 18(1):42-7. PubMed ID: 25603872
[TBL] [Abstract][Full Text] [Related]
2. [Advances on driver oncogenes of squamous cell lung cancer].
Hong W; Zhang Y
Zhongguo Fei Ai Za Zhi; 2014 May; 17(5):433-6. PubMed ID: 24854563
[TBL] [Abstract][Full Text] [Related]
3. Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.
Bar J; Damianovich M; Hout Siloni G; Dar E; Cohen Y; Perelman M; Ben Nun A; Simansky D; Yellin A; Urban D; Onn A
Clin Lung Cancer; 2014 Mar; 15(2):159-65. PubMed ID: 24370118
[TBL] [Abstract][Full Text] [Related]
4. [Driven Gene in Patients with Lung Squamous Cell Carcinoma:
Analysis of Clinicopathologic Characteristics and Prognosis].
Zhang T; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
[TBL] [Abstract][Full Text] [Related]
5. Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer.
Xiao D; Lu C; Zhu W; He Q; Li Y; Fu C; Zhou J; Liu S; Tao Y
Oncotarget; 2016 Sep; 7(37):59049-59057. PubMed ID: 27322143
[TBL] [Abstract][Full Text] [Related]
6. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
[TBL] [Abstract][Full Text] [Related]
7. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.
Cooper WA; O'toole S; Boyer M; Horvath L; Mahar A
Pathology; 2011 Feb; 43(2):103-15. PubMed ID: 21233671
[TBL] [Abstract][Full Text] [Related]
8. [Advances on driver oncogenes of lung adenocarcinoma].
Wang J; Zhang Z; Zhang S
Zhongguo Fei Ai Za Zhi; 2013 Feb; 16(2):91-6. PubMed ID: 23425901
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
11. Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations.
Lim JU; Yeo CD; Rhee CK; Kim YH; Park CK; Kim JS; Kim JW; Lee SH; Kim SJ; Yoon HK; Kim TJ; Lee KY
PLoS One; 2015; 10(11):e0142306. PubMed ID: 26555338
[TBL] [Abstract][Full Text] [Related]
12. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
Liang Y; Wakelee HA; Neal JW
Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: An effort to explore new drug targets.
Veldore VH; Patil S; Satheesh CT; Shashidhara HP; Tejaswi R; Prabhudesai SA; Krishnamoorthy N; Hazarika D; Naik R; Rao RM; Ajai Kumar BS
Indian J Cancer; 2015; 52(2):243-8. PubMed ID: 26853422
[TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples.
Reynolds JP; Zhou Y; Jakubowski MA; Wang Z; Brainard JA; Klein RD; Farver CF; Almeida FA; Cheng YW
Cancer Cytopathol; 2017 Mar; 125(3):178-187. PubMed ID: 28085233
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for NSCLC with driver mutations.
Minuti G; D'Incecco A; Cappuzzo F
Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
[TBL] [Abstract][Full Text] [Related]
16. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
17. Concurrent driver mutations/rearrangements in non-small-cell lung cancer.
Tabchi S; Kourie HR; Klastersky J
Curr Opin Oncol; 2017 Mar; 29(2):118-122. PubMed ID: 28027105
[TBL] [Abstract][Full Text] [Related]
18. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
[TBL] [Abstract][Full Text] [Related]
19. ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients.
Tuononen K; Kero M; Mäki-Nevala S; Sarhadi VK; Tikkanen M; Wirtanen T; Rönty M; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2014 Nov; 53(11):895-901. PubMed ID: 24942490
[TBL] [Abstract][Full Text] [Related]
20. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
Paweletz CP; Sacher AG; Raymond CK; Alden RS; O'Connell A; Mach SL; Kuang Y; Gandhi L; Kirschmeier P; English JM; Lim LP; Jänne PA; Oxnard GR
Clin Cancer Res; 2016 Feb; 22(4):915-22. PubMed ID: 26459174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]